Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas

Molecular and Cellular Endocrinology

Volumn 284, Issue 1-2, 2008, Pages 21-27

  Dvorakova, S ^a   Vaclavikova, E ^a   Sykorova, V ^a   Vcelak, J ^a   Novak, Z ^a   Duskova, J ^b   Ryska, A ^b   Laco, J ^b   Cap, J ^b   Kodetova, D ^b   Kodet, R ^b   Krskova, L ^b   Vlcek, P ^b   Astl, J ^b   Vesely, D ^b   Bendlova, B ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Genetics; Medullary thyroid carcinoma; Prognosis; RET proto oncogene; Somatic mutation

Indexed keywords

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CZECH REPUBLIC; EXON; FEMALE; GENE DELETION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; ONCOGENE RET; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MEDULLARY; COHORT STUDIES; CZECH REPUBLIC; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 39649096941     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.12.016     Document Type: Article

References (46)

1. Alemi M., Lucas S.D., Sallstrom J.F., Bergholm U., Akerstrom G., and Wilander E. A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma. Oncogene 14 (1997) 2041-2045
2. Bockhorn M., Frilling A., Kalinin V., Schröder S., and Broelsch C.E. No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. Langenbecks Arch. Surg. 384 (1999) 60-64
3. Bongarzone I., Vigano E., Alberti L., Mondellini P., Uggeri M., Pasini B., Borrello M.G., and Pierotti M.A. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Oncogene 18 (1999) 4833-4838
4. Bugalho M.J., Frade J.P., Santos J.R., Limbert E., and Sobrinho L. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Eur. J. Endocrinol. 136 (1997) 423-426
5. Carlomagno F., and Santoro M. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J. Chemother. 16 (2004) 49-51
6. Carlomagno F., Vitagliano D., Guida T., Napolitano M., Vecchio G., Fusco A., Gazit A., Levitzki A., and Santoro M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 62 (2002) 1077-1082
7. Ceccherini I., Pasini B., Pacini F., Gullo M., Bongarzone I., Romei C., Santamaria G., Matera I., Mondellini P., Scopsi L., Pinchera A., Pierotti M.A., and Romeo G. Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. Oncogene 14 (1997) 2609-2612
8. Cohen M.S., Hussain H.B., and Moley J.F. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132 (2002) 960-966
9. Costa P., Domingues R., Sobrinho L.G., and Bugalho M.J. RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population. Endocrine 27 (2005) 239-243
10. De Groot J.W.B., Links T.P., Plukker J.T.M., Lips C.J.M., and Hofstra R.M.W. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrinol. Rev. 27 (2006) 535-560
11. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., and Wells Jr. S.A. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2 (1993) 851-856
12. Dvorakova S., Vaclavikova E., Sykorova V., Duskova J., Vlcek P., Ryska A., Novak Z., and Bendlova B. New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma. Thyroid 16 (2006) 311-316
13. Elisei R., Cosci B., Romei C., Bottici V., Sculli M., Lari R., Barale R., Pacini F., and Pinchera A. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J. Clin. Endocrinol. Metab. 89 (2004) 3579-3584
14. Eng C., Mulligan L.M., Smith D.P., Healey C.S., Frilling A., Raue F., Neumann H.P., Pfragner R., Behmel A., and Lorenzo M.J. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12 (1995) 209-212
15. Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J., Stonehouse T.J., Poder M.A., Jackson C.E., Waterfield M.D., and Poder B.A.J. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10 (1995) 509-513
16. Eng C., Mulligan L.M., Healey C.S., Houghton C., Frilling A., Raue F., Thomas G.A., and Ponder B.A. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res. 56 (1996) 2167-2170
17. Eng C., Thomas G.A., Neuberg D.S., Mulligan L.M., Healey C.S., Houghton C., Frilling A., Raue F., Williams E.D., and Ponder B.A. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 83 (1998) 4310-4313
18. Frisk T., Zedenius J., Lundberg J., Wallin G., Kytölä S., and Larsson C. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome. Int. J. Oncol. 18 (2001) 1219-1225
19. Gimm O., Dziema H., Brown J., Hoang-Vu C., Hinze R., Dralle H., Mulligan L.M., and Eng C. Over-representation of a germline variant in the gene encoding RET co-receptor GFRalpha-1 but not GFRalpha-2 or GFRalpha-3 in cases with sporadic medullary thyroid carcinoma. Oncogene 20 (2001) 2161-2170
20. Gimm O., Dziema H., Brown J., de la Punte A., Hoang-Vu C., Dralle H., Plass C., and Eng C. Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. Int. J. Cancer 92 (2001) 70-74
21. Greene F.L., Page D.L., Fleming I.D., Fritz A.G., Balch C.M., Halley D.G., and Morrow M. AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors. 6th ed. (2002), Springer-Verlag, New York
22. Hofstra R.M., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Hoppener J.W., van Amstel H.K., and Romeo G. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
23. Hofstra R.M., Stelwagen T., Stulp R.P., de Jong D., Hulsbeek M., Kamsteeg E.J., van den Berg A., Landsvater R.M., Vermey A., Molenaar W.M., Lips C.J., and Buys C.H. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J. Clin. Endocrinol. Metab. 81 (1996) 2881-2884
24. Jhiang S.M., Fithian L., Weghorst C.M., Clark O.H., Falko J.M., O'Dorisio T.M., and Mazzaferri E.L. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 6 (1996) 115-121
25. Jindrichova S., Kodet R., Krskova L., Vlcek P., and Bendlova B. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J. Mol. Med. 81 (2003) 819-823
26. Jindrichova S., Vcelak J., Vlcek P., Neradilova M., Nemec J., and Bendlova B. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J. Endocrinol. 183 (2004) 257-265
27. Kalinin V., and Frilling A. 27 bp deletion in the RET proto-oncogene as a somatic mutation associated with medullary thyroid carcinoma. J. Mol. Med. 76 (1998) 365-367
28. Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N., Hosch S.B., Garkavtseva R.F., and Izbicki J.R. Three novel mutations in the RET proto-oncogene. J. Mol. Med. 79 (2001) 609-612
29. Komminoth P., Muletta-Feurer S., Saremaslani P., Kunz E.K., Matias-Guiu X., Hiort O., Schroder S., Seelentag W.K., Roth J., and Heitz P.U. Molecular diagnosis of multiple endocrine neoplasia (MEN) in paraffin-embedded specimens. Endocrinol. Pathol. 6 (1995) 267-278
30. Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G., Colomer A., Roth J., and Heitz P.U. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 76 (1995) 479-489
31. Maeda S., Namba H., Takamura N., Tanigawa K., Takahashi M., Noguchi S., Nagataki S., Kanematsu T., and Yamashita S. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas. Endocrinol. J. 42 (1995) 245-250
32. Marsh D.J., Learoyd D.L., Andrew S.D., Krishnan L., Pojer R., Richardson A.L., Delbridge L., Eng C., and Robinson B.G. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 44 (1996) 249-257
33. Marsh D.J., Theodosopoulos G., Martin-Schulte K., Richardson A.L., Philips J., Röher H.D., Delbridge L., and Robinson B.G. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 88 (2003) 1866-1872
34. Montani M., Schmidt A.M., Schmidt S., Lochem T., Saremaslani P., Hertz P.U., Komminoth P., and Perren A. No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocr. Relat. Cancer 12 (2005) 1011-1016
35. Musholt T.J., Hanack J., Brehm C., von Wasielewski R., and Musholt P.B. Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J. Surg. 29 (2005) 472-482
36. Oriola J., Halperin I., Rivera-Fillat F., and Donis-Keller H. The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial. J. Endocrinol. Invest. 25 (2002) 25-31
37. Romei C., Elisei R., Pinchera A., Ceccherini I., Molinaro E., Mancusi F., Martino E., Romeo G., and Pacini F. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J. Clin. Endocrinol. Metab. 81 (1996) 1619-1622
38. Ruiz A., Antinolo G., Fernandez R.M., Eng C., Marcos I., and Borrego S. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin. Endocrinol. (Oxf.) 55 (2001) 399-402
39. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Nathan N.A., Grieco M., Fusco A., Vecchio G., Matýskova B., and Kraus M.H. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 267 (1995) 381-383
40. Scurini C., Quadro L., Fattoruso O., Verga U., Libroia A., Lupoli G., Cascone E., Marzano L., Paracchi S., Busnardo B., Girelli M.E., Bellastella A., and Colantuoni V. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol. Cell. Endocrinol. 137 (1998) 51-57
41. Shan L., Nakamura M., Nakamura Y., Utsunomiya H., Shou N., Jiang X., Jing X., Yokoi T., and Kakudo K. Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas. Jpn. J. Cancer Res. 89 (1998) 883-886
42. Uchino S., Noguchi S., Adachi M., Sato M., Yamashita H., Watanabe S., Murakami T., Toda M., Murakami N., and Yamashita H. Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas. Jpn. J. Cancer Res. 89 (1998) 411-418
43. Uchino S., Noguchi S., Yamashita H., Sato M., Adachi M., Yamashita H., Watanabe S., Ohshima A., Mitsuyama S., Iwashita T., and Takahashi M. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn. J. Cancer Res. 90 (1999) 1231-1237
44. Wohllk N., Cote G.J., Bugalho M.M., Ordonez N., Evans D.B., Goepfert H., Khorana S., Schultz P., Richards C.S., and Gagel R.F. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81 (1996) 3740-3745
45. Zedenius J., Larsson C., Bergholm U., Bovee J., Svensson A., Hallengren B., Grimelius L., Backdahl M., Weber G., and Wallin G. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J. Clin. Endocrinol. Metab. 80 (1995) 3088-3090
46. Zedenius J., Wallin G., Hamberger B., Nordenskjöld M., Weber G., and Larsson C. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum. Mol. Genet. 3 (1994) 1259-1262